PCP
HZNP

Proficio Capital Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Proficio Capital Partners’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-119
Closed -$3K – 1942
2019
Q2 		$3K Hold
119
– – ﹤0.01% 1486
2019
Q1 		$3K Buy
+119
New +$2.82K ﹤0.01% 1310

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Proficio Capital Partners's HZNP Position: Q3 2019 in Review

Proficio Capital Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2019, closing a stake of 119 shares — an estimated $3K sold.

Proficio Capital Partners first reported a position in HZNP in Q1 2019 and held it in 2 quarters. The position peaked at $3K in Q2 2019. 264 funds tracked by Wall St. Rank hold HZNP as of Q3 2019.

  • Proficio Capital Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2019 after selling out during the quarter.
  • Proficio Capital Partners sold 119 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2019, an estimated $3K.
  • Proficio Capital Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and held it in 2 quarters.
  • Proficio Capital Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3K in Q2 2019.
  • 264 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2019.

Based on Proficio Capital Partners's 13F filing for Q3 2019, filed 13 Nov 2019.